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Abstract
Background: Patients with congenital blood platelet disorders (CPDs) demonstrate a 
predominantly mucocutaneous bleeding tendency. Repeated bleeds throughout life 
can have a significant impact on health status–related quality of life (HR-QoL), but 
few studies have investigated HR-QoL in patients with CPDs.
Objectives: To determine HR-QoL in patients with suspected or confirmed CPDs as 
compared with the general Dutch population and to assess the association between 
bleeding phenotype and HR-QoL.
Methods: Data were derived from the Thrombocytopathy in the Netherlands (TiN) 
study, a cross-sectional study of individuals suspected for a congenital platelet de-
fect. TiN patients with an increased ISTH Bleeding Assessment Tool (ISTH-BAT) 
score (>3 in men and > 5 in women) were included for analysis. HR-QoL was assessed 
with the Short Form (SF)-36 survey. Bleeding symptoms were evaluated with the 
ISTH-BAT, resulting in a bleeding score.
Results: One hundred fifty-six patients were analyzed, of whom 126 (81%) were 
women. Sixty-two patients (40%) had a confirmed CPD. Compared to the general 
Dutch population, patients with a suspected or confirmed CPD reported decreased 
physical functioning, limitations in daily activities due to physical health problems, 
limitations in social activities, decreased energy levels and fatigue, pain, and lower 
general health status. HR-QoL was not correlated with the ISTH-BAT score and was 
similar in patients with a confirmed CPD and those in whom a CPD could not be 
diagnosed.
Conclusion: A bleeding tendency in patients with a suspected or confirmed CPD sig-
nificantly impacts HR-QoL, independent of a confirmed explanatory diagnosis.
K E Y W O R D S
bleeding tendency, congenital blood platelet disorders, health status, quality of life, SF-36
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1  | INTRODUCTION
Congenital blood platelet disorders (CPDs) are disorders of primary 
hemostasis and can be due to defects in the adhesion, activation, 
secretion, or aggregation of platelets.1 Patients typically present 
with mucocutaneous bleeds or persistent bleeding following a he-
mostatic challenge such as dental extraction, invasive procedures, or 
childbirth.2 Although a study on the overall prevalence of CPDs has 
never been undertaken, it is suggested that it is similar to that of von 
Willebrand disease (VWD).3
Repeated bleeds throughout life can have a significant impact 
on quality of life, since it can hinder activities of daily living, social 
functioning, and educational achievements. Health status–related 
quality of life (HR-QoL) is a multidimensional concept for evaluat-
ing the physical, mental, emotional, and social health of an individ-
ual.4 Assessment of HR-QoL has become increasingly important in 
patient-centered care, since it provides valuable information on the 
impact of the disease on daily activities and can guide clinical deci-
sion making.5 In contrast to hemophilia and VWD,6‒9 information on 
HR-QoL in patients with CPDs is lacking.
The aim of the present study was to assess HR-QoL in adult pa-
tients with suspected or confirmed CPDs as compared with the gen-
eral Dutch population and to study the association between HR-QoL 
and bleeding phenotype. To our knowledge, this is the first study on 
HR-QoL in a large cohort of patients with suspected or confirmed 
CPDs.
2  | METHODS
2.1 | Thrombocytopathy in the Netherlands study
Data were derived from the Thrombocytopathy in the Netherlands 
(TiN) study. The TiN study is a nationwide cross-sectional study to 
collect data on clinical characteristics, functional assays, and genet-
ics in a real-life population of patients with suspected or confirmed 
congenital platelet disorders. Inclusion and exclusion criteria of the 
TiN study can be found in Appendix S1. In all included patients, 
laboratory tests were performed for platelet count, aggregation 
to 4 agonists (ADP, arachidonic acid, collagen, ristocetin), platelet 
ADP and ATP content, mepacrine staining, surface receptor ex-
pression with flow cytometry, and genetic analysis with a selected 
primary hemostasis gene panel. Platelet morphology, gray plate-
lets, and leukocyte inclusion bodies were assessed in a peripheral 
blood smear.
2.2 | Participant selection
For the current study, we evaluated data from TiN patients with 
a bleeding tendency defined as an increased ISTH Bleeding 
Assessment Tool (ISTH-BAT) score (>3 in men and > 5 in women.10) 
We included new patients suspected for a CPD, as well as patients 
with a previously confirmed CPD. These patients are referred to as 
“study group patients.” We excluded patients diagnosed with an ac-
quired platelet defect.
2.3 | ISTH bleeding assessment tool
The bleeding phenotype was assessed with the ISTH-BAT, admin-
istered by experienced physicians. The ISTH-BAT systematically 
evaluates 14 different bleeding symptoms, scored on a scale ranging 
from 0 to 4 points, and results in an ISTH-BAT bleeding score (BS).11 
Higher scores indicate a more severe bleeding phenotype.
2.4 | Short Form-36
HR-QoL was assessed with the Dutch version of the Short Form 
(SF)-36 survey. The SF-36 is a generic measure assessing 8 physi-
cal and mental health domains: physical and social functioning, 
role limitations due to physical or emotional problems, general 
health, mental health, bodily pain, and vitality (Table S1)12,13. For 
each domain, scores are converted to a 0-100 scale, with higher 
values reflecting a better quality of life. Control data from the 
general Dutch population were obtained from a nationwide health 
status survey.14
2.5 | Brief Illness Perception Questionnaire
The Dutch language version of the Brief Illness Perception 
Questionnaire (B-IPQ) was used to assess the cognitive and emo-
tional representations of illness. The 9 dimensions of the B-IPQ in-
clude consequences, timeline, personal control, treatment control, 
identity, concern, understanding, emotional response, and causal 
factors (Table S2). All of the dimensions except causal factors are 
rated on a linear scale from 0 to 10. Higher scores reflect a more 
negative (unfavorable) illness perception, except for the dimen-
sions personal control, treatment control, and understanding, 
where a higher score indicates a more positive (favorable) illness 
Essentials
• Repeated bleeds throughout life can have a significant impact on health status–related quality of life (HR-QoL).
• HR-QoL was evaluated in patients with suspected or confirmed congenital blood platelet disorders (CPD).
• Patients showed lower Short Form-36 scores on several domains as compared to the general Dutch population.
• A bleeding tendency in patients with a suspected or confirmed CPD significantly impacts HR-QoL.
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perception.15 Control data from the general Dutch population were 
not available.
2.6 | Definitions
The term study group patients refers to all patients included in the cur-
rent study, that is, new patients suspected for a CPD where a diagnosis 
could not be confirmed, as well as patients with a confirmed CPD. In 
the TiN study, a confirmed CPD was diagnosed when abnormal plate-
let function was found on at least 2 occasions, of which one was in our 
diagnostic laboratory. These patients are referred to as confirmed CPD 
patients. A bleeding tendency was defined as an increased ISTH-BAT 
score (>3 in adult men and > 5 in adult women.10) Comorbidity was 
defined as the presence of one or more conditions with a duration of 
at least 6 months in the last year16 and was self-reported.
2.7 | Statistical analyses
Statistical analyses were performed with IBM SPSS Statistics 25 and 
RStudio version 0.99. Descriptive results were presented as medi-
ans (interquartile ranges [IQRs]) for continuous data and frequencies 
(percentages) for categorical data. Differences in SF-36 scores be-
tween study group patients and the general Dutch population were 
evaluated with linear regression analyses adjusted for age, sex, and 
comorbidity as other determinants of HR-QoL. For each SF-36 do-
main, a linear regression was performed, with the SF-36 domain as 
outcome and group (general population or study group patient) as 
determinant. A significance level of P ≤ 0.01 was used to correct for 
multiple comparisons. Correlations between SF-36 domains and the 
ISTH-BAT score (as a proxy for bleeding phenotype), between B-IPQ 
dimensions and the ISTH-BAT score and between B-IPQ dimensions 
and the SF-36 domain general health perception were calculated with 
nonparametric Spearman’s rank correlation. Correlation coefficients 
(ρ) of 0.20 to 0.39 were considered weak, 0.40 to 0.59 moderate, 0.60 
to 0.79 strong and > 0.8 very strong.17 Only moderate or stronger cor-
relations were considered relevant.
3  | RESULTS
3.1 | Patient characteristics
A total of 200 patients were included in the TiN cohort, of whom 31 
did not have an objective bleeding tendency and 6 were diagnosed 
with an acquired platelet defect. Thus, 163 patients with a suspected 
or confirmed CPD and an objective bleeding tendency were included 
for the current analysis, of whom 156 patients completed the ques-
tionnaire and were included in the study group. Patient characteris-
tics are shown in Table 1. The majority of patients were women (81%). 
The median age was 44 years for women (IQR, 31-55) and 45 years for 
men (IQR, 31-61). The median BS was 11 for women (IQR, 9-14) and 
10 for men (IQR, 7-13). A CPD was confirmed in 62 of 156 patients 
(40%). The most commonly observed comorbidities were hyperten-
sion (17%), type 2 diabetes mellitus (6%), and endometriosis (4%).
3.2 | Health-related quality of life
Compared to the general Dutch population, study group patients 
reported decreased physical functioning and limitations in the 
type or amount of regular daily activities due to physical health 
problems. They also reported limitations in social activities, de-
creased energy levels and fatigue, pain, and lower general health 
status (Figure 1 and Table S3). HR-QoL was similar in patients with 
a confirmed CPD and those in whom a CPD could not be diagnosed 
(Table S4). Women reported significantly more pain than men. The 
other domain scores were not significantly different between men 
and women.
3.3 | Association between HR-QoL and 
bleeding phenotype
The ISTH-BAT score, as a proxy for bleeding phenotype, was not 
correlated with any of the SF-36 domains (Table S5) nor with any of 
the B-IPQ dimensions (Table S6).
TA B L E  1   Patient characteristics
  
General Dutch populationa 
n = 1742
Study groupb patients 
n = 156
Confirmed CPD 
patientsc n = 62
Sex Women, n (%) 761 (44) 126 (81) 41 (66)
Age Men, median (IQR) 49 (36-63) 45 (31-61) 53 (32-63)
Women, median (IQR) 41 (30-60) 44 (31-55) 45 (32-57)
Bleeding score Men, median (IQR) NA 10 (7-13) 10 (6-14)
Women, median (IQR) NA 11 (9-14) 11 (9-17)
Comorbidity Yes, n (%) 856 (49) 92 (59) 34 (55)
Abbreviations: CPD, congenital blood platelet disorder; IQR, interquartile range; NA, not available.
aSee Aaronson et al.14 
bPatients included in the study with a suspected or confirmed CPD. 
cStudy group patients in whom a CPD was confirmed. 
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3.4 | Brief illness perception questionnaire
Perceiving more consequences of bleeds, perceiving more physical 
complaints due to bleeds, perceiving more concerns about bleeds, 
and perceiving a more extreme emotional response to bleeds were 
associated with lower general health perception (Table 2).
4  | DISCUSSION
To our knowledge, this is the first study on HR-QoL in a large co-
hort of patients with suspected or confirmed CPDs. Our patients 
reported decreased physical functioning, limitations in the type or 
amount of regular daily activities due to physical health problems, 
limitations in social activities, decreased energy levels and fatigue, 
pain, and lower general health status as compared with the general 
Dutch population. HR-QoL was similar in patients with a confirmed 
CPD and those in whom a CPD could not be diagnosed and was not 
associated with the ISTH-BAT score. More negative illness percep-
tions were related to lower general health perceptions.
The domain general health reflects the perception of general 
health status. Patients with a suspected or confirmed CPD may be-
lieve their health is poor and likely to get worse due to recurrent 
bleeds and hospital visits. This might especially be true for patients 
without a definitive diagnosis, due to insecurity about their current 
and future health status. Also, patients perceiving more conse-
quences of bleeds, more physical complaints due to bleeds, more 
concerns about bleeds, or a more extreme emotional response to 
bleeds experienced lower general health status. The domain vitality 
measures energy levels and fatigue. Especially women with CPDs 
might experience fatigue due the development of iron-deficient 
anemia as a consequence of menorrhagia. The decrease in energy 
levels could also account for lower levels of social activity. The lower 
scores in the domains physical functioning, role limitations due to 
physical problems, and bodily pain are more difficult to explain, as in 
general, mucocutaneous bleeds do not induce physical impairment 
or pain. It could not be explained by the bleeding phenotype, since 
there was no correlation between the SF-36 domain scores and the 
ISTH-BAT score. Possibly, HR-QoL scores were influenced by ill-
ness perception. It is generally understood that HR-QoL and illness 
perception are related,18‒20 and we found negative correlations be-
tween the SF-36 domain general health perception and the B-IPQ 
domains consequences, identity, concern, and emotional response. 
F I G U R E  1   Health status-related 
quality of life. Differences in SF-36 
domain scores between study group 
patients and thegeneral Dutch population 
were evaluated with linear regression 
analysis adjusted for age, sex and 
comorbidity. Error bars represent the IQR. 
BP, bodily pain; CPD, congenital blood 
platelet disorder; GH, general health; 
IQR, interquartile range; MH, mental 
health; PF, physical functioning; RE, role 
limitations due to emotional problems; RP, 
role limitations due to physical problems; 
SF, social functioning; SF-36, Short Form-
36; VT, vitality. *P-value ≤ 0.01
100
General Dutch population






















PF RP BP GH VT
Domains
SF RE MH
TA B L E  2   Correlation between B-IPQ dimensions and SF-36 
domain general health perception









Note: Interpretation: Perceiving more consequences of bleeds is 
associated with lower general health perception.
Abbreviations: B-IPQ, Brief Illness Perception Questionnaire; SF, Short 
Form.
aCorrelation coefficients of ≥ 0.40 and ≤−0.40 were considered 
relevant. 
104  |     BLAAUWGEERS Et AL.
Possibly, patients were anxious to exercise because they feared 
bleeds and therefore felt physically impaired.
Previous studies on HR-QoL in patients with bleeding disorders 
mostly focused on patients with von Willebrand disease and hemo-
philia or on women with menstrual disorders.21‒24 Only a few studies 
included a limited number of patients with CPDs.25,26 These stud-
ies used questionnaires other than the SF-36 to assess HR-QoL and 
are therefore not comparable. Patients with VWD, another primary 
hemostasis defect with similar clinical characteristics, reported a re-
duced HR-QoL for the domains general health and vitality.9 HR-QoL 
in patients with VWD was mainly affected by acute bleeds. This is 
in contrast to haemophilia, where HR-QoL depends on long-term 
effects, such as orthopedic status, comorbidities and hepatitis C in-
fection27,28 and where the domains physical functioning and general 
health were most affected.7
There was a risk for selection bias. There is no database or reg-
istry for congenital platelet disorders in the Netherlands. Patients 
included in the study were mainly patients who recently visited a he-
mophilia treatment center. Besides that, patients with a more severe 
bleeding phenotype were perhaps more willing to participate in the 
study. Therefore, milder types of CPDs are likely underrepresented 
in our study population. This could explain the lower HR-QoL in our 
patients as compared to the general population. However, in our 
analysis, HR-QoL was not correlated with the bleeding phenotype.
We reported no correlation between the ISTH-BAT score and 
domains of the SF-36. A possible explanation for this finding is that 
the ISTH-BAT score and HR-QoL capture different time frames: 
the ISTH-BAT score reflects symptoms throughout one’s entire 
life, regardless of the symptoms still being present, while the SF-36 
measures one’s health status in the preceding weeks to months. A 
patient with a high ISTH-BAT score due to severe bleeding problems 
in the past can have a relatively good quality of life due to the ab-
sence of bleedings in the past year. Another possible explanation is 
that only patients with an increased ISTH-BAT score were included 
and, as mentioned before, milder types of CPDs with lower ISTH-
BAT scores were likely underrepresented in our study population. As 
a result, the calculated correlation coefficient might not reflect the 
true correlation between ISTH-BAT score and HR-QoL, since certain 
data are missing.
A major challenge of HR-QoL evaluation is the interpretation of 
the observed differences. A difference of 3 to 5 points has been con-
sidered clinically relevant.29 However, although scores for the SF-36 
domains range from 0 to 100, for some domains the score range is 
limited due to dichotomous answers, and therefore it does not seem 
defensible to use this 3- to 5-point difference for all domains.
Evaluating HR-QoL has become increasingly important in pa-
tient-centered care because it will help to comprehend the patient’s 
perspective on the disease. Our patients showed an impaired HR-
QoL independent of a confirmed CPD, indicating that a bleeding 
tendency is a considerable health problem on its own. Even after 
extensive laboratory testing, as advised by the ISTH,30 many pa-
tients remain without a definitive diagnosis due to the complexity of 
platelet function testing. Accurately informing patients about their 
condition and treatment options and creating awareness among 
other physicians might improve the HR-QoL of patients with a bleed-
ing disorder, even those without a definitive diagnosis. In addition, 
proper counseling of patients may modify the patient’s perception of 
illness, which could improve their HR-QoL.
For future studies, it could be interesting to assess changes in 
HR-QoL from time of initial diagnosis, to explore whether education 
on the disease will benefit these patients. Since different populations 
may vary in their perception of health and associated comorbidities, 
it will be useful to conduct similar studies in other populations.
In conclusion, our study showed that a bleeding tendency in pa-
tients with a suspected or confirmed CPD significantly impacts HR-
QoL, independent of a confirmed explanatory diagnosis and that this 
patient group is one to care for.
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